{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:24:24Z","timestamp":1756383864457,"version":"3.30.1"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"vor","delay-in-days":204,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/j.lrr.2024.100473","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T12:46:52Z","timestamp":1721825212000},"page":"100473","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Olaparib induced aplastic anemia in a patient with castrate resistant prostate cancer: A case report"],"prefix":"10.1016","volume":"22","author":[{"given":"Elrazi A","family":"Ali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akriti","family":"Pokhrel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Unni","family":"Mooppan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9623-6645","authenticated-orcid":false,"given":"Jen chin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.lrr.2024.100473_bib0001","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.lrr.2024.100473_bib0002","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/bcp.12761","volume":"81","author":"Goulooze","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"9","key":"10.1016\/j.lrr.2024.100473_bib0003","doi-asserted-by":"crossref","first-page":"e391","DOI":"10.3324\/haematol.2016.146522","article-title":"Aplastic anemia: the correct nomenclature matters","volume":"101","author":"Cuglievan","year":"2016","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.lrr.2024.100473_bib0004","doi-asserted-by":"crossref","first-page":"534","DOI":"10.7326\/0003-4819-136-7-200204020-00011","article-title":"Acquired aplastic anemia","volume":"136","author":"Young","year":"2002","journal-title":"Ann. Intern. Med."},{"issue":"5","key":"10.1016\/j.lrr.2024.100473_bib0005","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.23.01868","article-title":"FDA approval summary: olaparib in combination with abiraterone for treatment of patients with BRCA-mutated metastatic castration-resistant prostate cancer","volume":"42","author":"Fallah","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lrr.2024.100473_bib0006","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejca.2022.04.016","article-title":"Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: further analyses from the PROfound study","volume":"170","author":"Roubaud","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.lrr.2024.100473_bib0007","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S1470-2045(22)00017-1","volume":"23","author":"Thiery-Vuillemin","year":"2022","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.lrr.2024.100473_bib0008","doi-asserted-by":"crossref","first-page":"e1137","DOI":"10.1016\/j.clgc.2017.07.005","article-title":"Acute myeloid leukemia after olaparib treatment in metastatic castration-resistant prostate cancer","volume":"15","author":"Zhu","year":"2017","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.lrr.2024.100473_bib0009","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1093\/ajcp\/aqx121.160","article-title":"161 therapy-related acute erythroid leukemia after olaparib treatment","volume":"149","author":"Liu","year":"2018","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.lrr.2024.100473_bib0010","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1200\/JCO.2018.36.15_suppl.5548","volume":"36","author":"Korach","year":"2018","journal-title":"JCO"},{"key":"10.1016\/j.lrr.2024.100473_bib0011","article-title":"Myelodysplastic syndrome\/acute myeloid leukemia following the use of poly-ADP ribose polymerase (PARP) inhibitors: a real-world analysis of postmarketing surveillance data","volume":"13","author":"Zhao","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"23","key":"10.1016\/j.lrr.2024.100473_bib0012","doi-asserted-by":"crossref","first-page":"5211","DOI":"10.1158\/1078-0432.CCR-22-1622","article-title":"Therapy-related myeloid neoplasms following PARP inhibitors: real-life experience","volume":"28","author":"Marmouset","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.lrr.2024.100473_bib0013","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1016\/S2352-3026(20)30360-4","article-title":"Myelodysplastic syndrome and acute myeloid leukemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database","volume":"8","author":"Morice","year":"2021","journal-title":"Lancet Haematol."},{"issue":"2","key":"10.1016\/j.lrr.2024.100473_bib0014","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1016\/S2352-3026(20)30360-4","article-title":"Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database","volume":"8","author":"Morice","year":"2021","journal-title":"Lancet Haematol."},{"issue":"8","key":"10.1016\/j.lrr.2024.100473_bib0015","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","article-title":"Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial","volume":"34","author":"Ray-Coquard","year":"2023","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.lrr.2024.100473_bib0016","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1002\/cam4.5062","article-title":"Hematological toxicities in PARP inhibitors: a real-world study using FDA adverse event reporting system (FAERS) database","volume":"12","author":"Shu","year":"2023","journal-title":"Cancer Med."}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048924000633?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048924000633?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T20:37:28Z","timestamp":1733431048000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213048924000633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":16,"alternative-id":["S2213048924000633"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2024.100473","relation":{},"ISSN":["2213-0489"],"issn-type":[{"type":"print","value":"2213-0489"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Olaparib induced aplastic anemia in a patient with castrate resistant prostate cancer: A case report","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2024.100473","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100473"}}